Ligand Pharmaceuticals (LGNDZ) Leases (2019 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Leases for 7 consecutive years, with $5.2 million as the latest value for Q4 2025.
- Quarterly Leases fell 25.41% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 25.41% year-over-year, with the annual reading at $5.2 million for FY2025, 25.41% down from the prior year.
- Leases hit $5.2 million in Q4 2025 for Ligand Pharmaceuticals, down from $7.6 million in the prior quarter.
- In the past five years, Leases ranged from a high of $24.7 million in Q2 2022 to a low of $800000.0 in Q1 2025.
- Historically, Leases has averaged $8.1 million across 5 years, with a median of $6.7 million in 2021.
- Biggest five-year swings in Leases: soared 293.42% in 2021 and later tumbled 86.73% in 2025.
- Year by year, Leases stood at $3.2 million in 2021, then rose by 24.61% to $4.0 million in 2022, then skyrocketed by 51.55% to $6.1 million in 2023, then rose by 13.94% to $6.9 million in 2024, then fell by 25.41% to $5.2 million in 2025.
- Business Quant data shows Leases for LGNDZ at $5.2 million in Q4 2025, $7.6 million in Q3 2025, and $8.0 million in Q2 2025.